Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.6%

77 terminated/withdrawn out of 373 trials

Success Rate

78.1%

-8.4% vs industry average

Late-Stage Pipeline

32 trials in Phase 3/4

Results Transparency

86%

236 of 275 completed trials have results

Key Signals

236 with results63 terminated14 withdrawn

Enrollment Performance

Analytics

Phase 1

185(51.0%)

Phase 2

141(38.8%)

Phase 3

28(7.7%)

Phase 4

4(1.1%)

N/A

4(1.1%)

Early Phase 1

1(0.3%)

363Total

Phase 1(185)

Phase 2(141)

Phase 3(28)

Phase 4(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (373)

Showing 20 of 373 trials

NCT01242267Phase 1Completed

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

Role: collaborator

NCT02114229Phase 2Active Not Recruiting

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors

Role: collaborator

NCT00492050Phase 2Active Not Recruiting

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

Role: collaborator

NCT02339922Phase 2Active Not Recruiting

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Role: collaborator

NCT01919086Phase 2Completed

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Role: collaborator

NCT00378105Phase 1Active Not Recruiting

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT01208662Phase 3Active Not Recruiting

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Role: collaborator

NCT02312102Phase 1Completed

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

Role: collaborator

NCT00590200Active Not Recruiting

GeneBank at the Cleveland Clinic: Molecular Determinants of Coronary Artery Disease

Role: collaborator

NCT02441686Phase 2Completed

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT01809691Phase 3Completed

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Role: collaborator

NCT02461888Phase 2Completed

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Role: collaborator

NCT02253316Phase 2Active Not Recruiting

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Role: collaborator

NCT00310037Phase 2Completed

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Role: collaborator

NCT01659658Phase 3Terminated

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Role: lead

NCT04051827Phase 1Completed

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT00734877Phase 3Active Not Recruiting

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Role: collaborator

NCT02765854Phase 2Completed

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Role: collaborator

NCT00329589Phase 1Completed

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Role: collaborator

NCT02186509Phase 1Completed

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Role: collaborator